November 17th 2024
At the SDPA Fall Conference, Miranti emphasized the importance of targeted, comprehensive acne therapies and inspired attendees to embrace pediatric dermatology as a rewarding subspecialty.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
FDA clamps down hard to tighten Accutane access
September 6th 2005National report -- The Food and Drug Administration (FDA) has placed unprecedented restrictions on the acne drug Accutane (Roche) by requiring patients who use it, as well as those who prescribe and dispense it, to enroll in a national registry and follow other stringent rules.
Certain pediatric skin diseases more likely in children with skin of color
September 1st 2005Children with skin of color are also especially likely to develop hypo- or hyperpigmentary changes after resolution of lesions of a dermatosis or secondary to other forms of skin trauma, including treatments administered for skin disorders.
TriLuma combination effective for PIH
September 1st 2005Kissimmee, Fla. — With recent developments in the treatment of hyperpigmentation, Dr. Roger Ceilley, clinical professor of dermatology at the University of Iowa and past president of the American Academy of Dermatology and the American Society for Dermatologic Surgery, provided further insight into the management of post-inflammatory hyperpigmentation.
Hormonal role in pigmentation studied
September 1st 2005Tokyo — There is the possibility that sex hormones and sex hormone-binding globulin (SHBG) may regulate melanogenesis, a recent finding that may change the way in which pigmentation is viewed, according to Taketsugu Tadokoro, M.D., Ph.D., director, department of dermatology, Osaka National Hospital, Osaka-shi, Japan.